Overview

Effects of PF-07901801,Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Status:
Not yet recruiting

Trial end date:
2025-10-18

Target enrollment:

Participant gender:

Summary

The purpose of this study is to learn about the effects of three study medicines (PF-07901801, tafasitamab, and lenalidomide) when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that: - is relapsed (has returned after last treatment) or - is refractory (has not responded to last treatment) DLBCL is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes. These lymphocytes are a type of white blood cell that normally help to fight infections. This study is seeking participants who are unable or unwilling to undergo a stem cell transplant. Stem cell transplant is when doctors put healthy blood cells back into your body. Everyone in this study will receive all three medicines. Participants will receive PF-07901801 and tafasitamab at the study clinic by intravenous (IV) infusion (given directly into a vein). Study interventions will be administered in 28-day cycles. PF-0791801 will be given weekly for the first three cycles and then every two weeks. Tafasitamab will administered on Days 1, 4, 8, 15 and 22 in cycle 1, weekly in cycles 2 and 3 and then every 2 weeks in cycle 4 and beyond. Lenalidomide will be taken by mouth at home every day for Days 1 to 21 of each 28-day cycle for the first 12 cycles. Participants can continue to take PF-07901801 and tafasitamab until their lymphoma is no longer responding. Lenalidomide is discontinued after 12 cycles. PF-07901801 will be given at different doses to different participants. Everyone taking part will receive approved doses of tafasitamab and lenalidomide. We will compare the experiences of people receiving different doses of PF-07901801. This will help us to determine what dose is safe and effective dose when combined with the other 2 study medicines.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Collaborators:

Incyte Corporation
MorphoSys AG

Treatments:

Lenalidomide